Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rinatabart sesutecan versus investigator's choice in platinum-resistant ovarian cancer
NL-OMON59714Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rinatabart sesutecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Genmab. Primary endpoint: Progression-Free Survival. Started Oct 2025; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON59714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59714.